产品说明书
Tozadenant
 |
同义名 : | SYN115 |
| CAS号 : | 870070-55-6 | |
| 货号 : | A100067 | |
| 分子式 : | C19H26N4O4S | |
| 纯度 : | 98+% | |
| 分子量 : | 406.499 | |
| MDL号 : | MFCD21642026 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(123 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Tozadenant is an adenosine A2A receptor antagonist, with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00783276 | Cocaine Dependence | Early Phase 1 | Completed | - | United States, Texas ... 展开 >> University of Texas Health Science Center at Houston Houston, Texas, United States, 77030 收起 << |
| NCT01283594 | Parkinson's Disease | Phase 2 Phase 3 | Completed | - | - |
| NCT00605553 | Parkinson's Disease | Phase 2 | Completed | - | United States, Missouri ... 展开 >> Washington University St. Louis Saint Louis, Missouri, United States, 63110 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.46mL 0.49mL 0.25mL |
12.30mL 2.46mL 1.23mL |
24.60mL 4.92mL 2.46mL |
| 参考文献 |
|---|